HBOT Conversations:
Dr. Paul Harch & The Science Behind The Practice
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on The Science Behind the Practice is the fourth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
di Girolamo asks Dr. Harch to explain his background, and the road he had to take to get to where he is today.
In Episode 4, Dr. Harch tells a miraculous story of how his medical journey with Hyperbaric Oxygen Therapy fell into his lap during his surgical residency. It was during this internship when Dr, Harch was in a horrendous vehicle accident and nearly killed. This led to more than one medical leave of absence. While out on his second leave of absence after yet another surgery, his perspective changed; and he started to wonder what he wanted to do with his life.
After not finding fulfilment in an emergency medicine practice, Dr. Harch decided that he needed to follow his true passion and interest if he was going to have any chance of feeling accomplished, and changing lives.
Dr. Harch had a high level of interest in Navy divers and the extreme cases of brain decompression sickness. He started asking questions about how they were being treated for decompression sickness and why they were not getting better. Dr, Harch refers to the unbelievable cases that landed in his lap as his “Manna from Heaven”. Other doctors tossed these cases to the side, but Dr. Harch decided to try something different with these patients – he treated using lower doses of hyperbaric oxygen therapy. It totally reversed what was going on with these patients!
Even though his results were clinically astonishing, the Medical Societies were surprisingly not impressed or welcoming; forcing Dr. Harch to create more research documentation and do more clinical work to prove his success with hyperbaric oxygen therapy to treat chronic brain issues. During his journey to prove the results, he was implemental in successfully being able to show brain decompression illness on imaging. The imaging results were so dramatic after hyperbaric oxygen therapy that the radiologists didn’t even know how to read it! This is about the time when Dr. Harch’s road to patient care took a straight-shot towards healing a larger variety of indications with HBOT.
His goal today is the same as it was back then…. prove to everyone that Hyperbaric Oxygen Therapy WORKS! Dr. Harch has no plans to retire and stresses that he wants to see this all over the finish line.
Dr. Harch has used HBOT to change the lives of children and adults; but it was his own life that was also greatly changed by the power of hyperbarics. Hyperbaric Oxygen Therapy has allowed Dr. Harch to take the elements of oxygen and pressure, & implement them into healing protocols that have now saved countless lives.
Subscribe Now, It’s Free !
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Rehabilitation of the patients with osteoarthritis.
Under the term “osteoarthritis” (OA) is currently meant a clinical syndrome resulting from the combined effect of articular pain and disordered functional activity leading to the deterioration of the quality of life of the patients. The principal objective of rehabilitation of the patients presenting with GA in which all patients with this condition are in need practically after each next aggravation of the pathological process is to relive pain syndrome and restore the functional ability of the joints lost or deteriorated after each exacerbation in order to eventually improve the quality of life of the patients experiencing the constantly progressing degenerative process in the musculoskeletal system.
A rare case of primary necrotising fasciitis of the breast: combined use of hyperbaric oxygen and negative pressure wound therapy to conserve the breast. Review of literature.
Abstract: Necrotising fasciitis is a rare but potentially fatal disease. It is even more unusual as a primary disease of the breast. Surgical treatment is required in order to gain control over the spreading infection and mastectomy is reported to be the most common...
Clinical Trial – Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for
mobilizing hematopoietic progenitor cells from bone marrow to blood. These cells are needed
for patients to undergo bone marrow transplantation and some patients fail to respond to
current best chemotherapy. HBO2 has been shown to trigger stem cell mobilization in other
patient populations and we plan to investigate whether this intervention can act in concert
with chemotherapeutic agents to allow poor mobilizer patients to achieve successful bone
marrow transplantation. Twenty patients will be identified by participating hematologists who
have failed to respond adequately to chemotherapy. When it is deemed appropriate to attempt
an additional stem cell mobilization protocol, these patients will be administered
chemotherapy as determined by their primary treating hematologist and additionally receive
daily HBO2 (2.5 atmospheres absolute [ATA] for 90 minutes) for 3-8 days. At intervals, blood
samples will be obtained as is the normal transplantation protocol practice to assess whether
adequate stem cells are present in blood for the patient to proceed with transplantation. The
project is anticipated to take one year to complete.